Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

Nanoparticle-based co-delivery systems combine two or more therapeutic agents within a single nanoscale carrier to achieve synergistic anticancer effects, reduce systemic toxicity and overcome drug resistance. By co-encapsulating chemotherapeutics, gene modulators or chemosensitisers in a unified vehicle, controlled release profiles can be achieved in response to pH, redox potential or other microenvironmental cues. Such platforms range from polymeric micelles and lipid-based nanocarriers to mesoporous silica and hybrid nanogels. Advantages include improved solubility of hydrophobic drugs, prolonged circulation times, enhanced tumour localisation via the enhanced permeability and retention effect and reduced off-target exposure. Engineering of surface ligands further permits active targeting of tumour receptors, while rational design of core–shell architectures allows sequential release of cargos. Together, these innovations hold promise for more effective combination regimens, personalised dosing and minimisation of adverse effects in solid and haematological malignancies worldwide.

Research from Nature Portfolio

Innovative mesoporous silica nanoparticles have been developed to overcome targeted therapy resistance in epidermal growth factor receptor-mutant lung cancer. A dual-drug nano-medicine was engineered by capping silica pores with a monoclonal antibody fragment, enabling selective uptake by receptor-overexpressing tumour cells and subsequent release of a tyrosine kinase inhibitor alongside a chemotherapeutic payload. High intratumoral accumulation, efficient intracellular drug liberation driven by redox gradients and potent inhibition of resistant xenograft progression demonstrate the potential of antibody-guided, pore-tuned silica carriers to surmount acquired resistance mechanisms and enhance treatment durability.

Nanoparticle-Based Co-Delivery Systems for Cancer Therapy publication trend

The graph below shows the total number of articles in nanoparticle-based co-delivery systems for cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Co-delivery system: A nanoscale platform designed to carry and release two or more therapeutic agents simultaneously or sequentially at the disease site.

Micelle: A self-assembled colloidal structure formed by amphiphilic polymers or lipids, featuring a hydrophobic core for drug loading and a hydrophilic shell for solubility.

Mesoporous silica nanoparticle: A rigid, porous inorganic particle with tunable pore sizes that can encapsulate multiple cargos and enable controlled release.

Enhanced permeability and retention (EPR) effect: A phenomenon by which nanoparticles preferentially accumulate in tumours due to leaky vasculature and poor lymphatic drainage.

π-π stacking: A non-covalent interaction between aromatic rings that can stabilise hydrophobic drug cores within polymeric carriers.

References

1. Co-delivery of doxorubicin and hydroxychloroquine via chitosan/alginate nanoparticles for blocking autophagy and enhancing chemotherapy in breast cancer therapy. Frontiers in Pharmacology (2023).
2. Engineering Docetaxel Micelles for Enhanced Cancer Therapy Through Intermolecular Forces. Bioengineering (2024).
3. Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Scientific Reports (2016).
4. Co-Delivery System of Curcumin and Colchicine Using Functionalized Mesoporous Silica Nanoparticles Promotes Anticancer and Apoptosis Effects. Pharmaceutics (2022).